News Article | April 27, 2017
A single transplant of microbes contained in the stool of a healthy donor is a safe and effective way to increase diversity of good bacteria in the guts of patients with ulcerative colitis, according to new research from Weill Cornell Medicine and NewYork-Presbyterian. The findings suggest that fecal microbiota transplantation (FMT) might be an effective treatment for the disease, which causes inflammation and ulcers in the digestive tract. Fecal microbiota transplantation is a procedure in which fecal matter -- which is full of bacteria from the gut -- is collected from a healthy donor, strained and placed in the colon of a patient with inflammatory bowel disease. "The idea is that you can change someone's microbiome, the organisms that colonize the gut," said Dr. Randy Longman, an assistant professor of medicine at Weill Cornell Medicine and a gastroenterologist at NewYork-Presbyterian/Weill Cornell Medical Center. "We introduce good bacteria into the intestines of someone with the disease and hope that it encourages healing." FMT has been proven effective for patients with Clostridium difficile, a serious bacterial infection of the intestines, but questions remain about its effectiveness as a treatment for other diseases. In a study published April 26 in Inflammatory Bowel Disease, a team of gastroenterologists and researchers from Weill Cornell Medicine and NewYork-Presbyterian led by Drs. Vinita Jacob, Carl Crawford and Longman present data suggesting that FMT is safe and increases the diversity of microbes in patients with active ulcerative colitis. "Patients with ulcerative colitis typically have a lower diversity of microbes in their guts," said Dr. Longman, who is also a scientist in the Jill Roberts Institute for Research in Inflammatory Bowel Disease and a clinician in the Jill Roberts Center for Inflammatory Bowel Disease at NewYork-Presbyterian/Weill Cornell and Weill Cornell Medicine. "We know that a more diverse microbiota is correlated with better health, so increasing that diversity may be a key factor in the therapeutic efficacy of FMT for ulcerative colitis." The researchers used a fecal microbiota preparation (FMP) consisting of stool from two different healthy donors that had been screened and purified. This two-donor preparation was used in order to maximize the diversity of bacteria in the transplant. They then used a colonoscopy to transplant the FMP into the colons of 20 ulcerative colitis patients. After four weeks, the investigators collected fecal samples from the patients and performed rectal biopsies in order to measure the fecal microbiome and immune response after treatment. The researchers found that after four weeks, the bacterial populations in the intestines of the patients more closely resembled those of the healthy donors than the patients' original microbiomes. In addition, the treatment also resulted in a reduction in the inflammatory response that drives ulcerative colitis. Overall, 35 percent of patients showed a clinical improvement in their symptoms and 15 percent of patients achieved clinical remission (complete lack of symptoms) by the end of the four-week study. "We still want to know why this treatment helps some patients and not others so that we can find a safer and more reproducible treatment option for a greater majority of patients suffering from ulcerative colitis," said Dr. Crawford, an assistant professor of clinical medicine. Further studies are necessary to determine how long these positive effects may last in ulcerative colitis patients, the exact bacteria that might be most effective for FMP and the most effective delivery method. This study provides promising results for the emerging role for FMT in ulcerative, Dr. Longman said. "We saw clear positive effects, both in terms of increased bacterial population and in clinical response. This points to FMT as an exciting possible therapy for people with ulcerative colitis."
News Article | April 20, 2017
When the kidneys - vital organs for filtering the body's entire blood supply - become injured, it can set in motion an unfortunate chain of events that leads to a decline in health. Sometimes, in response to chronic injury, the body begins an aberrant repair process known as fibrosis, in which normal fibroblast cells transform into myofibroblasts, proliferate out of control, migrate and form scar tissue. Once scar tissue begins to form, functional cells begin to die, and the scar tissue multiplies. Investigators have been looking for a way to break this cycle, and new findings indicate that a gene known as SMOC2 may point the way to a new intervention that could prevent this cascade of events. Previous studies by investigators at Brigham and Women's Hospital had identified SMOC2 as a protein that was highly upregulated in the kidneys of mice with fibrosis. In a new study published in JCI Insights, investigators report that increasing SMOC2 in the kidney helped initiate and continue the progression of kidney fibrosis, while tamping down SMOC2 prevented it. To test this, researchers overexpressed SMOC2 in a mouse model of kidney fibrosis and performed RNA sequencing to investigate the mechanisms responsible for fibrotic development. They found that SMOC2 activated a fibroblast-to-myofibroblast transition (FMT). The team then used two approaches to "silence" SMOC2 - a genetic approach, by using SMOC2 knockout mice, and a pharmacologic approach, by administering SMOC2 siRNA. Using these approaches, researchers were successful in tamping down the protein's production, which protected against fibrosis development. Corresponding author Vishal Vaidya, PhD, of BWH's Renal Division, notes that one of the exciting things about SMOC2 is that it can be detected in a patient's urine. Now that a functional connection between the protein and kidney fibrosis is becoming clearer, SMOC2 is looking like an increasingly useful biomarker for detecting fibrosis. In addition, SMOC2 may be a promising therapeutic target for an unmet medical need. "We want to be able to intervene before the tissue becomes severely fibrotic to the point of no return. Our investigation indicates that SMOC2 could be a key to protecting against kidney fibrosis initiation and progression," said Vaidya. This work was made possible through funding by the Partners Innovation Discovery Grant, Outstanding New Environmental Sciences, Innovation in Regulatory Science Award from Burroughs Wellcome Fund, the Harvard Catalyst, the National Institutes of the Health, the National Institute of Environmental Health Sciences, the Harvard Medical School Laboratory of Excellence in Systems Pharmacology and the Giovanni Armenise-Harvard Foundation.
News Article | April 25, 2017
Harper and FMT to team up on integrating patented microwave technologies to enable advanced material processing furnace systems(PRWeb April 25, 2017)Read the full story at http://www.prweb.com/releases/2017/04/prweb14255142.htm
News Article | May 3, 2017
Thermal processing specialist Harper International, and Ferrite Microwave Technologies, which supplies 915 MHz industrial microwave systems, have formed a strategic relationship. Harper will make use of FMT’s high power microwave heating technology for its gas and electric fired furnaces. FMT reportedly has several patented microwave technologies that enable improved microwave field distribution across a wide variety of materials. Harper will integrate FMT’s heating technology into its furnace systems. Since commercial microwave use requires material specific equipment, matching the engineering and design capabilities of FMT with Harper’s furnace systems will help match customers’ processing requirements, the companies say. ‘Microwave can be a highly efficient and effective solution for a range of materials including ceramic and metal powders,’ said Charles Miller, president at Harper. ‘To provide our customers with an expanded solution set via world class microwave components inside our proven furnace systems is a winning combination.’ This story is reprinted from material from Harper, with editorial changes made by Materials Today. The views expressed in this article do not necessarily represent those of Elsevier.
News Article | April 28, 2017
Wiseguyreports.Com Adds “Passenger Boarding Bridges -Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2022” To Its Research Database Global Passenger Boarding Bridges market competition by top manufacturers/players, with Passenger Boarding Bridges sales volume, Price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Passenger Boarding Bridges for these regions, from 2012 to 2022 (forecast), covering On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into Glass Walled Passenger Boarding Bridges Steel Walled Passenger Boarding Bridges On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Passenger Boarding Bridges for each application, including Airport Seaport Global Passenger Boarding Bridges Sales Market Report 2017 1 Passenger Boarding Bridges Market Overview 1.1 Product Overview and Scope of Passenger Boarding Bridges 1.2 Classification of Passenger Boarding Bridges by Product Category 1.2.1 Global Passenger Boarding Bridges Market Size (Sales) Comparison by Type (2012-2022) 1.2.2 Global Passenger Boarding Bridges Market Size (Sales) Market Share by Type (Product Category) in 2016 1.2.3 Glass Walled Passenger Boarding Bridges 1.2.4 Steel Walled Passenger Boarding Bridges 1.3 Global Passenger Boarding Bridges Market by Application/End Users 1.3.1 Global Passenger Boarding Bridges Sales (Volume) and Market Share Comparison by Application (2012-2022) 1.3.2 Airport 1.3.3 Seaport 1.4 Global Passenger Boarding Bridges Market by Region 1.4.1 Global Passenger Boarding Bridges Market Size (Value) Comparison by Region (2012-2022) 1.4.2 United States Passenger Boarding Bridges Status and Prospect (2012-2022) 1.4.3 China Passenger Boarding Bridges Status and Prospect (2012-2022) 1.4.4 Europe Passenger Boarding Bridges Status and Prospect (2012-2022) 1.4.5 Japan Passenger Boarding Bridges Status and Prospect (2012-2022) 1.4.6 Southeast Asia Passenger Boarding Bridges Status and Prospect (2012-2022) 1.4.7 India Passenger Boarding Bridges Status and Prospect (2012-2022) 1.5 Global Market Size (Value and Volume) of Passenger Boarding Bridges (2012-2022) 1.5.1 Global Passenger Boarding Bridges Sales and Growth Rate (2012-2022) 1.5.2 Global Passenger Boarding Bridges Revenue and Growth Rate (2012-2022) 9 Global Passenger Boarding Bridges Players/Suppliers Profiles and Sales Data 9.1 JBT Aerotech 9.1.1 Company Basic Information, Manufacturing Base and Competitors 9.1.2 Passenger Boarding Bridges Product Category, Application and Specification 188.8.131.52 Product A 184.108.40.206 Product B 9.1.3 JBT Aerotech Passenger Boarding Bridges Sales, Revenue, Price and Gross Margin (2012-2017) 9.1.4 Main Business/Business Overview 9.2 ThyssenKrupp Access Solutions 9.2.1 Company Basic Information, Manufacturing Base and Competitors 9.2.2 Passenger Boarding Bridges Product Category, Application and Specification 220.127.116.11 Product A 18.104.22.168 Product B 9.2.3 ThyssenKrupp Access Solutions Passenger Boarding Bridges Sales, Revenue, Price and Gross Margin (2012-2017) 9.2.4 Main Business/Business Overview 9.3 Hyundai Rotem 9.3.1 Company Basic Information, Manufacturing Base and Competitors 9.3.2 Passenger Boarding Bridges Product Category, Application and Specification 22.214.171.124 Product A 126.96.36.199 Product B 9.3.3 Hyundai Rotem Passenger Boarding Bridges Sales, Revenue, Price and Gross Margin (2012-2017) 9.3.4 Main Business/Business Overview 9.4 MHI 9.4.1 Company Basic Information, Manufacturing Base and Competitors 9.4.2 Passenger Boarding Bridges Product Category, Application and Specification 188.8.131.52 Product A 184.108.40.206 Product B 9.4.3 MHI Passenger Boarding Bridges Sales, Revenue, Price and Gross Margin (2012-2017) 9.4.4 Main Business/Business Overview 9.5 FMT 9.5.1 Company Basic Information, Manufacturing Base and Competitors 9.5.2 Passenger Boarding Bridges Product Category, Application and Specification 220.127.116.11 Product A 18.104.22.168 Product B 9.5.3 FMT Passenger Boarding Bridges Sales, Revenue, Price and Gross Margin (2012-2017) 9.5.4 Main Business/Business Overview 9.6 ADELTE 9.6.1 Company Basic Information, Manufacturing Base and Competitors 9.6.2 Passenger Boarding Bridges Product Category, Application and Specification 22.214.171.124 Product A 126.96.36.199 Product B 9.6.3 ADELTE Passenger Boarding Bridges Sales, Revenue, Price and Gross Margin (2012-2017) 9.6.4 Main Business/Business Overview 9.7 CEL 9.7.1 Company Basic Information, Manufacturing Base and Competitors 9.7.2 Passenger Boarding Bridges Product Category, Application and Specification 188.8.131.52 Product A 184.108.40.206 Product B 9.7.3 CEL Passenger Boarding Bridges Sales, Revenue, Price and Gross Margin (2012-2017) 9.7.4 Main Business/Business Overview 9.8 ShinMaywa 9.8.1 Company Basic Information, Manufacturing Base and Competitors 9.8.2 Passenger Boarding Bridges Product Category, Application and Specification 220.127.116.11 Product A 18.104.22.168 Product B 9.8.3 ShinMaywa Passenger Boarding Bridges Sales, Revenue, Price and Gross Margin (2012-2017) 9.8.4 Main Business/Business Overview 9.9 CIMC 9.9.1 Company Basic Information, Manufacturing Base and Competitors 9.9.2 Passenger Boarding Bridges Product Category, Application and Specification 22.214.171.124 Product A 126.96.36.199 Product B 9.9.3 CIMC Passenger Boarding Bridges Sales, Revenue, Price and Gross Margin (2012-2017) 9.9.4 Main Business/Business Overview 9.10 Vataple 9.10.1 Company Basic Information, Manufacturing Base and Competitors 9.10.2 Passenger Boarding Bridges Product Category, Application and Specification 188.8.131.52 Product A 184.108.40.206 Product B 9.10.3 Vataple Passenger Boarding Bridges Sales, Revenue, Price and Gross Margin (2012-2017) 9.10.4 Main Business/Business Overview 9.11 PT Bukaka Teknik Utama TBK 9.12 ShinMaywa Industrial For more information, please visit https://www.wiseguyreports.com/sample-request/1080663-global-passenger-boarding-bridges-sales-market-report-2017
News Article | February 21, 2017
Diversified Machine Systems (DMS), headquartered in Colorado, manufactures the highest quality 5 axis and 3 axis CNC machines in the industry. DMS has recently created a new design in their Freedom Machine Tool product line. This new machine, the FMT Plus, provides a greater degree of versatility without sacrificing rigidity. This FMT Plus machine offers a Z axis of up to 15 inches, an increase from its previous top-line FMT router by eight inches. This enables customers to route materials having greater levels of height and thicknesses such as plastic, dense wood and foam composites. The FMT Plus is comprised of a fully stress-relieved, laser-calibrated steel frame. The frame is then outfitted with 30mm motion rails on both the X and Y axis’s. These are driven by 30mm and 40mm ball-screw assemblies, respectively. This precision engineering ensures a durable, long-lasting, high-quality routing machine. “Designing this machine was more than simply adding more Z axis height to an existing FMT machine. To ensure we maintained the quality FMT is known for, our engineers redesigned the machine to fully-incorporate the additional Z axis height into a completely new machine," says FMT sales and marketing manager, Andrew Townsend. Freedom Machine Tool, a division of Diversified Machine Systems (DMS), is a manufacturer of affordable, 3 axis CNC routers. Freedom Machine Tool was founded to address the need in the market for a cost-effective, industrial quality CNC machining solution without sacrificing on quality or reliability. Freedom Machine Tool manufactures the Patriot 4x4 CNC Router, Patriot 4x8 CNC Router, Patriot 4x8 Lathe, Patriot 5x10 CNC Router for the woodworking industry, the Orthorout 4x4 and 4x8 for the orthotics industry and the Office Machining Center for the medical office manufacturing industry.
News Article | February 23, 2017
SOMERVILLE, Mass.--(BUSINESS WIRE)--OpenBiome, a public stool bank, announced today that it has entered into a collaboration with Finch Therapeutics, a microbiome biopharmaceutical company, to enable FDA approval of a fecal transplant pill for the treatment of recurrent C. difficile infection. Finch will be licensing OpenBiome’s biomanufacturing quality systems and incorporating manufacturing upgrades as well as its own drug delivery technology to prepare the product for clinical trials and eventual marketing authorization. Since delivering its first treatment in October 2013, OpenBiome has distributed more than 21,000 treatments to its network of over 800 hospitals and clinics. Fecal microbiota transplantation (FMT) is used to treat C. difficile infections that are not responsive to antibiotic therapies. C. difficile is the most common hospital-acquired infection in the country, affecting 453,000 patients a year, and resulting in an estimated 29,000 deaths. 1 in 5 patients do not respond to first-line antibiotics. For patients who fail multiple courses of antibiotic treatment, fecal transplantation has been shown to prevent recurrence in more than 85% of cases. OpenBiome was founded to expand safe access to fecal transplantation for patients with recurrent C. difficile infection and to catalyze research on the role of the microbiome in human health. The stool bank provides clinicians with rigorously screened, ready-to-use stool microbiota preparations and supports researchers with a suite of tools to discover how gut bacteria might treat diseases beyond C. difficile. When it launched, patients in need of fecal transplants often had to travel significant distances for a visit to one of the few fecal transplant practitioners in the country. Today, more than 97% of the US population lives within a two-hour drive of a provider using OpenBiome material to perform FMT. An interim policy from the U.S. Food and Drug Administration (FDA) allows physicians to perform FMT for the treatment of recurrent C. difficile infection, despite the fact that the therapy is not FDA-approved. Medical professional societies and clinical researchers advocated for the policy based on the available literature on FMT’s safety and efficacy and the lack of treatment alternatives for this patient population. “To preserve patient access to this treatment option, and given the scale that we’ve reached, demonstrating the safety and efficacy of fecal transplantation through adequate and well-controlled clinical trials is the right thing to do,” explained Carolyn Edelstein, OpenBiome’s director of Outreach and Public Affairs, in an op-ed published earlier today with the Fecal Transplant Foundation. OpenBiome will continue to supply clinicians and researchers with material, manufactured by Finch, under prevailing FDA policy and in support of its nonprofit mission to enable patient access and research. Under the terms of the collaboration, OpenBiome will license its quality system for biomanufacturing to Finch. Finch will incorporate its novel drug delivery technology to enable the targeted release of microbes at the site of the C. difficile infection in the colon. Finch will also upgrade the manufacturing system to support FDA approval, and will provide material produced in this improved quality environment to OpenBiome. FIN-403 is the lead product candidate emerging from this partnership. Finch expects to begin enrolling for a Phase II clinical trial to evaluate the safety and efficacy of FIN-403 for the prevention of recurrence in recurrent C. difficile patients in the second half of 2017. OpenBiome will receive a series of upfront payments, ongoing milestone payments, and royalties on sales of FIN-403 and other products developed in the collaboration. With these resources, OpenBiome will support early-stage, high-risk, long-term microbiome research programs that might not be able to secure traditional funding. With this additional funding for its independent research program, OpenBiome will work to advance public knowledge on how gut bacteria can be engineered to help cure or even prevent disease. Dr. Mark Smith, PhD, OpenBiome’s co-founder and research director, will be stepping down from his roles at OpenBiome to serve as the CEO at Finch. He will maintain a seat on the OpenBiome Board of Directors and serve as an advisor to OpenBiome’s Scientific Review Board. “This affiliation will allow us to execute our mission at a level we could not have imagined before,” said James Burgess, OpenBiome’s Executive Director, in a letter to OpenBiome’s clinicians and researchers. “Through it, we will provide safe access to fecal transplantation for patients with recurrent C. difficile today, and help Finch pursue FDA approval so that patients have this access in perpetuity. OpenBiome will continue to catalyze research in the microbiome by providing clinical investigators with logistical and material support, and by facilitating the kind of discoveries that will help cure or even prevent disease. We are thrilled by the path ahead.” About OpenBiome OpenBiome is the first public stool bank, founded to expand safe access to fecal transplantation for patients with recurrent C. difficile infection and to catalyze research on the microbiome’s role in human health. OpenBiome provides clinicians with rigorously screened, ready-to-use stool preparations and supports researchers with a suite of tools to discover how gut bacteria might treat diseases beyond C. difficile. Since 2013, OpenBiome has partnered with over 800 healthcare institutions across all 50 states and 6 countries to deliver more than 21,000 treatments for recurrent C. difficile. Its research portfolio includes 49% of all U.S. trials exploring the use of fecal transplants in new diseases. About Finch Finch Therapeutics is a mission-driven biopharmaceutical company that aims to develop novel microbial therapies serving patients with serious and unmet medical needs. Founded by data scientists, clinicians, and microbiologists from MIT and OpenBiome, Finch uses machine-learning algorithms informed by high-throughput molecular data to reverse engineer successful experiences with fecal transplantation. Through this and other clinical datasets, Finch identifies the microbes that drive desirable patient outcomes, and develops therapies that deliver those microbial communities to the patient. As Finch’s first clinical-stage program, FIN-403 provides both a short-term opportunity for impacting C. difficile and a long-term platform for designing new therapies.
News Article | January 26, 2017
Fecal transplant may sound gross but according to a new study from Ohio State University, fecal transplants may actually be beneficial to children with autism. Fecal transplant, otherwise known as bacteriotherapy, is the method of introducing microbes from healthy donors into the gastrointestinal (GI) tract of people suffering from severe stomach problems, such as recurrent C. difficile colitis. Fecal transplant efficiently replenishes the good bacteria or probiotics that have been killed or suppressed, usually through the excessive use of antibiotics. In the study, the researchers used microbiota transfer therapy or fecal microbiota transplant (FMT). In FMT, fecal sample is collected from the healthy donor, mixed with a saline or other solution, filtered, and transferred to the patient via colonoscopy, endoscopy, sigmoidoscopy, or enema. "Transplants are working for people with other gastrointestinal problems. And, with autism, gastrointestinal symptoms are often severe, so we thought this could be potentially valuable," said Ann Gregory, one of the study's lead authors and a microbiology graduate student at The Ohio State University. The study, which is set to be published in the journal Microbiome, looked into 18 kids diagnosed with autism and moderate to severe GI conditions. Both doctors and parents reported that they saw positive changes in all of the participants' stomach health and behavior autism symptoms that lasted eight weeks after the fecal transplant treatment was done. Nevertheless, parents with autistic children should never attempt to do fecal transplant at home. "More research is needed before this can be used for treatment," Gregory warned. "Microbiota should be very carefully screened, and the treatment should be done under medical supervision." Gastrointestinal disorders are consistently seen among children diagnosed with autism spectrum disorder (ASD). Research shows 70 percent of the children with ASD had GI issues compared to 42 percent of the children with developmental disorder other than ASD. Autistic individuals, like everyone else, are also susceptible to gastritis, irritable bowel syndrome (IBS), and severe food allergies. The exact reason behind why GI disorders are more pervasive in children with autism is yet unknown. However, there is a push for researchers to focus their work on addressing autism during the early life of children. "Even though GI symptoms are common in early childhood, physicians should be mindful that children with ASD may be experiencing more GI difficulties in the first three years of life," autism researchers from Columbia University, wrote in the March 25 issue of the journal JAMA Psychiatry. © 2017 Tech Times, All rights reserved. Do not reproduce without permission.
News Article | February 24, 2017
FMT Consultants, a leading provider of integrated business management solutions and information technology services based in San Diego and Los Angeles, has announced that it has earned the Microsoft Silver Cloud Customer Relationship Management (CRM) Competency, bringing the firm’s total number of competencies from Microsoft to eight. Achieving the Microsoft Silver Cloud CRM Competency validates FMT as a premier provider of Microsoft Dynamics 365 (formerly Dynamics CRM Online)—Microsoft’s cloud-based customer relationship management solution. To achieve the Silver Cloud CRM Competency, FMT team members successfully completed exams and are now recognized Microsoft Certified Professionals. Additionally, FMT demonstrated its ability to deliver successful projects and assessments by exceeding several software revenue goals, and providing multiple customer references. “As a leading technology provider, we are constantly working to expand and deepen our expertise so that we can continue to help customers realize the full benefit of their solutions,” says Eric Casazza, CEO of FMT Consultants, and adds, “our goal is to make it easy for customers to migrate to the cloud and immediately see the positive impact on their business. Achieving the Microsoft Silver Cloud CRM Competency demonstrates our continued commitment and efforts to provide expert advice and excellent service to all our customers.” FMT Consultants has now achieved five Microsoft Gold Competencies: Gold Cloud Platform, Gold Cloud Productivity, Gold Content and Collaboration, Gold Customer Relationship Management, and Gold Enterprise Resource Planning. Microsoft Silver Competencies for the firm include the Silver Cloud Customer Relationship Management, Silver Midmarket Cloud Solutions, and Silver Application Development. About FMT Consultants FMT is a seasoned provider of integrated business solutions and information technology services throughout the US and Canada with a significant presence in San Diego County, Los Angeles County, and Orange County. Since 1995, FMT’s experienced team of experts has been partnering with clients to integrate, configure and customize innovative technology solutions to help them improve and streamline their business operations. The company has offices in Carlsbad and Los Angeles, CA. Visit http://www.fmtconsultants.com or call 760.930.6400 for more information.
News Article | February 15, 2017
Fitness Machine Technicians, specialists in the maintenance and repair of exercise equipment for gyms, corporations, hotels, and private residences, announced that Bruce Sturgeon of Doylestown, PA and Jack Brady of New Britain, PA acquired Bucks and Lehigh county markets. A technician for over ten years, Bruce Sturgeon has worked with Fitness Machine Technicians for the past four years. Originally from Baltimore, MD, he has been involved in the fitness industry for over 20 years. “I’ve had the pleasure of getting to know Bruce over the last few years and am excited about his new venture within Fitness Machine Technicians. We are happy he has chosen to stay a part of the team,” said founder and CEO, Don Powers. After learning about the unique opportunity from Sturgeon, Jack Brady, a Temple University graduate with a degree in business and over 25 years of sales experience, was eager to join. Sturgeon said, “Because Jack and I live in the area, we know the businesses and people who reside in this great community. We are providing a unique and needed service to our area—specifically servicing fitness machines owned by our own neighbors and friends.” Colleges, homes, hotel chains and recreation and fitness centers continue to expand their facilities to accommodate the growing interest in exercise as a part of ongoing wellness. Treadmills, elliptical, stationary bikes and stair steppers must be maintained to ensure their ongoing availability to members, residents and guests. Fitness Machine Technicians offers reliable service/repair and maintenance services on a variety of exercise equipment on a contract and non-contract basis. The company currently services counties including Philadelphia, Montgomery, Chester, Berks, Camden, Gloucester, and New Castle and is looking to expand further throughout the Mid-Atlantic region. Since beginning this business concept over ten years ago, the demand for services has expanded throughout the region. For private residences or public facilities, Fitness Machine Technicians customers can request a technician by calling 844-FMT-FIXX or via http://fitnessmachinetechnicians.com/request-a-tech/. About Fitness Machine Technicians Fitness Machine Technicians specializes in the maintenance and repair of equipment for commercial and home exercise facilities. In addition to providing basic service, parts replacement and maintenance on a contract or per call basis, the company also assists in the design of facilities, recommending equipment layouts for maximum functionality. Clients include health clubs, corporations, hotels, condos, education, government and residential throughout the Mid-Atlantic region. Fitness Machine Technicians also offers franchise opportunities to individuals with an interest in fitness and looking to run a service-based business based on a proven operating model. For more information, visit the website at http://www.fitnessmachinetechnicians.com or call 844-FMT-FIXX.